Verified factor-similar pair

JPSE vs SPSM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
92
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • JPSE has the higher backtested relative Sharpe (1.051 vs 1.027).
  • SPSM has the lower published fee (0.03% vs 0.29%).
  • SPSM has the stronger regression fit (adjusted R-squared 0.978 vs 0.973).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

JPSE

JPMorgan Diversified Return U.S. Small Cap Equity ETF
SMB
Adj. R2
0.973
Rel. Sharpe
1.051
Mkt beta
0.95
AUM
US$557M
MER
0.29%
Valuation
117

SPSM

State Street SPDR Portfolio S&P 600 Small Cap ETF
SMB
Adj. R2
0.978
Rel. Sharpe
1.027
Mkt beta
0.98
AUM
US$14.7B
MER
0.03%
Valuation
117

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
JPSE
+0.86
|t|
+22.2
SPSM
+0.91
|t|
+31.2
diff -0.05
HML
JPSE
+0.18
|t|
+5.4
SPSM
+0.19
|t|
+6.7
diff -0.00
RMW
JPSE
+0.19
|t|
+4.5
SPSM
+0.08
|t|
+2.4
diff +0.11
CMA
JPSE
+0.05
|t|
+1.0
SPSM
+0.01
|t|
+0.3
diff +0.04
UMD
JPSE
+0.04
|t|
+1.6
SPSM
+0.07
|t|
+3.5
diff -0.03

Why This Pair Matches

Exposure level
90
Exposure shape
100
Mkt beta diff
0.03
Rel. Sharpe diff
0.024

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

JPSE fund page SPSM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.